• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多基因风险评分可预测糖尿病并发症及其对强化血压和血糖控制的反应。

Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control.

机构信息

Department of Medicine, University of Montréal, CRCHUM, Québec, Canada.

The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.

出版信息

Diabetologia. 2021 Sep;64(9):2012-2025. doi: 10.1007/s00125-021-05491-7. Epub 2021 Jul 6.

DOI:10.1007/s00125-021-05491-7
PMID:34226943
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8382653/
Abstract

AIMS/HYPOTHESIS: Type 2 diabetes increases the risk of cardiovascular and renal complications, but early risk prediction could lead to timely intervention and better outcomes. Genetic information can be used to enable early detection of risk.

METHODS

We developed a multi-polygenic risk score (multiPRS) that combines ten weighted PRSs (10 wPRS) composed of 598 SNPs associated with main risk factors and outcomes of type 2 diabetes, derived from summary statistics data of genome-wide association studies. The 10 wPRS, first principal component of ethnicity, sex, age at onset and diabetes duration were included into one logistic regression model to predict micro- and macrovascular outcomes in 4098 participants in the ADVANCE study and 17,604 individuals with type 2 diabetes in the UK Biobank study.

RESULTS

The model showed a similar predictive performance for cardiovascular and renal complications in different cohorts. It identified the top 30% of ADVANCE participants with a mean of 3.1-fold increased risk of major micro- and macrovascular events (p = 6.3 × 10 and p = 9.6 × 10, respectively) and a 4.4-fold (p = 6.8 × 10) higher risk of cardiovascular death. While in ADVANCE overall, combined intensive blood pressure and glucose control decreased cardiovascular death by 24%, the model identified a high-risk group in whom it decreased the mortality rate by 47%, and a low-risk group in whom it had no discernible effect. High-risk individuals had the greatest absolute risk reduction with a number needed to treat of 12 to prevent one cardiovascular death over 5 years.

CONCLUSIONS/INTERPRETATION: This novel multiPRS model stratified individuals with type 2 diabetes according to risk of complications and helped to target earlier those who would receive greater benefit from intensive therapy.

摘要

目的/假设:2 型糖尿病会增加心血管和肾脏并发症的风险,但早期风险预测可以实现及时干预和改善预后。遗传信息可用于早期发现风险。

方法

我们开发了一个多基因风险评分(multiPRS),该评分由与 2 型糖尿病主要风险因素和结局相关的 598 个 SNP 组成的 10 个加权 PRS(10 wPRS)组成,这些 SNP 来自全基因组关联研究的汇总统计数据。将 10 wPRS、种族、性别、发病年龄和糖尿病病程的第一主成分纳入一个逻辑回归模型,以预测 ADVANCE 研究的 4098 名参与者和 UK Biobank 研究的 17604 名 2 型糖尿病患者的微血管和大血管结局。

结果

该模型在不同队列中对心血管和肾脏并发症具有相似的预测性能。它确定了 ADVANCE 参与者中前 30%的个体具有更高的主要微血管和大血管事件风险(平均风险比为 3.1 倍,p=6.3×10-5 和 p=9.6×10-5,分别),心血管死亡风险增加 4.4 倍(p=6.8×10-5)。尽管在 ADVANCE 研究中,强化血压和血糖控制综合降低了 24%的心血管死亡风险,但该模型确定了一个高危组,其中死亡率降低了 47%,而一个低危组则没有明显效果。高危个体的绝对风险降低最大,每 12 例患者接受治疗可预防 5 年内发生 1 例心血管死亡。

结论/解释:这种新型多PRS 模型根据并发症风险对 2 型糖尿病患者进行分层,并有助于针对那些从强化治疗中获益最大的患者进行早期治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d4/8382653/d566eb5fb93c/125_2021_5491_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d4/8382653/d11c22642a86/125_2021_5491_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d4/8382653/ad1b5b75901b/125_2021_5491_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d4/8382653/6b500561ff49/125_2021_5491_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d4/8382653/29244c02d2f1/125_2021_5491_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d4/8382653/d566eb5fb93c/125_2021_5491_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d4/8382653/d11c22642a86/125_2021_5491_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d4/8382653/ad1b5b75901b/125_2021_5491_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d4/8382653/6b500561ff49/125_2021_5491_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d4/8382653/29244c02d2f1/125_2021_5491_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d4/8382653/d566eb5fb93c/125_2021_5491_Fig5_HTML.jpg

相似文献

1
Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control.多基因风险评分可预测糖尿病并发症及其对强化血压和血糖控制的反应。
Diabetologia. 2021 Sep;64(9):2012-2025. doi: 10.1007/s00125-021-05491-7. Epub 2021 Jul 6.
2
A polygenic risk score derived from common variants of monogenic diabetes genes is associated with young-onset type 2 diabetes and cardiovascular-kidney complications.源自单基因糖尿病基因常见变异的多基因风险评分与早发型2型糖尿病及心血管-肾脏并发症相关。
Diabetologia. 2025 Feb;68(2):367-381. doi: 10.1007/s00125-024-06320-3. Epub 2024 Nov 23.
3
Development of genome-wide polygenic risk scores for lipid traits and clinical applications for dyslipidemia, subclinical atherosclerosis, and diabetes cardiovascular complications among East Asians.东亚人群脂质特征、血脂异常、亚临床动脉粥样硬化、糖尿病心血管并发症的全基因组多基因风险评分的开发及临床应用。
Genome Med. 2021 Feb 19;13(1):29. doi: 10.1186/s13073-021-00831-z.
4
Type 2 diabetes pathway-specific polygenic risk scores elucidate heterogeneity in clinical presentation, disease progression and diabetic complications in 18,217 Chinese individuals with type 2 diabetes.2型糖尿病通路特异性多基因风险评分揭示了18217例中国2型糖尿病患者在临床表现、疾病进展和糖尿病并发症方面的异质性。
Diabetologia. 2025 Mar;68(3):602-614. doi: 10.1007/s00125-024-06309-y. Epub 2024 Nov 12.
5
Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart Disease.腰臀比与心血管代谢特征、2型糖尿病和冠心病的遗传关联。
JAMA. 2017 Feb 14;317(6):626-634. doi: 10.1001/jama.2016.21042.
6
A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study.早期强化多因素治疗对筛查发现的2型糖尿病患者5年心血管结局影响及成本效益的随机试验:初级保健中筛查发现糖尿病患者强化治疗的英-丹-荷研究(ADDITION-Europe)
Health Technol Assess. 2016 Aug;20(64):1-86. doi: 10.3310/hta20640.
7
Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.药物预防 2 型糖尿病的微血管和大血管并发症:近期临床试验结果的意义。
Am J Cardiovasc Drugs. 2012 Feb 1;12(1):7-22. doi: 10.2165/11594650-000000000-00000.
8
Association of Genetic Variants Related to Gluteofemoral vs Abdominal Fat Distribution With Type 2 Diabetes, Coronary Disease, and Cardiovascular Risk Factors.与臀股部与腹部脂肪分布相关的遗传变异与 2 型糖尿病、冠心病及心血管风险因素的关联。
JAMA. 2018 Dec 25;320(24):2553-2563. doi: 10.1001/jama.2018.19329.
9
Integrating genome-wide polygenic risk scores and non-genetic risk to predict colorectal cancer diagnosis using UK Biobank data: population based cohort study.利用英国生物库数据整合全基因组多基因风险评分和非遗传风险来预测结直肠癌诊断:基于人群的队列研究。
BMJ. 2022 Nov 9;379:e071707. doi: 10.1136/bmj-2022-071707.
10
Effect of polygenic risk for schizophrenia on cardiac structure and function: a UK Biobank observational study.精神分裂症多基因风险对心脏结构和功能的影响:一项英国生物银行观察性研究。
Lancet Psychiatry. 2023 Feb;10(2):98-107. doi: 10.1016/S2215-0366(22)00403-5. Epub 2023 Jan 8.

引用本文的文献

1
Comparison of polygenic risk scores for type 2 diabetes developed from different ancestry groups.不同血统群体开发的2型糖尿病多基因风险评分的比较。
NPJ Metab Health Dis. 2025 May 3;3(1):17. doi: 10.1038/s44324-025-00059-0.
2
Diabetes mellitus polygenic risk scores: heterogeneity and clinical translation.糖尿病多基因风险评分:异质性与临床转化。
Nat Rev Endocrinol. 2025 Jun 4. doi: 10.1038/s41574-025-01132-w.
3
Genetic Insights Into Type 2 Diabetes Mellitus Susceptibility: A Case-Control Study of the rs1501299 Polymorphism in the Population of Noakhali Region of Bangladesh.

本文引用的文献

1
Economic Evaluation of a New Polygenic Risk Score to Predict Nephropathy in Adult Patients With Type 2 Diabetes.新多基因风险评分预测 2 型糖尿病成年患者肾病的经济学评价。
Can J Diabetes. 2021 Mar;45(2):129-136. doi: 10.1016/j.jcjd.2020.06.010. Epub 2020 Jun 17.
2
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.钠-葡萄糖协同转运蛋白 2 抑制剂在射血分数降低的心力衰竭患者中的应用:EMPEROR-Reduced 和 DAPA-HF 试验的荟萃分析。
Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30.
3
Genomic risk score offers predictive performance comparable to clinical risk factors for ischaemic stroke.
2型糖尿病易感性的遗传学见解:孟加拉国诺阿卡利地区人群中rs1501299多态性的病例对照研究。
Genet Res (Camb). 2025 May 24;2025:8818420. doi: 10.1155/genr/8818420. eCollection 2025.
4
The Spanish Polygenic Score reference distribution: a resource for personalized medicine.西班牙多基因评分参考分布:个性化医疗的一种资源。
Eur J Hum Genet. 2025 Apr 24. doi: 10.1038/s41431-025-01850-9.
5
Exploring the shared genetic landscape of diabetes and cardiovascular disease: findings and future implications.探索糖尿病与心血管疾病的共同遗传图谱:研究结果与未来启示
Diabetologia. 2025 Jun;68(6):1087-1100. doi: 10.1007/s00125-025-06403-9. Epub 2025 Mar 15.
6
Polygenic prediction for underrepresented populations through transfer learning by utilizing genetic similarity shared with European populations.通过利用与欧洲人群共享的遗传相似性,借助迁移学习对代表性不足的人群进行多基因预测。
Brief Bioinform. 2024 Nov 22;26(1). doi: 10.1093/bib/bbaf048.
7
Integrating Polygenic Risk Scores (PRS) for Personalized Diabetes Care: Advancing Clinical Practice with Tailored Pharmacological Approaches.整合多基因风险评分(PRS)用于个性化糖尿病护理:通过定制化药物治疗方法推进临床实践。
Diabetes Ther. 2025 Feb;16(2):149-168. doi: 10.1007/s13300-024-01676-6. Epub 2024 Dec 17.
8
Association of monocyte-lymphocyte ratio and myocardial infarction in the U.S. population with diabetes.美国糖尿病患者群体中单核细胞与淋巴细胞比值和心肌梗死的关联。
Front Cardiovasc Med. 2024 Sep 27;11:1432838. doi: 10.3389/fcvm.2024.1432838. eCollection 2024.
9
Risk of new-onset diabetes and efficacy of pharmacological weight loss therapy.新发糖尿病风险与药物减肥治疗的疗效。
Diabetes Obes Metab. 2024 Oct;26(10):4441-4449. doi: 10.1111/dom.15798. Epub 2024 Jul 26.
10
Higher Genetic Risk for Type 2 Diabetes Is Associated With a Faster Decline of β-Cell Function in an East Asian Population.东亚人群中,2 型糖尿病遗传风险越高β细胞功能下降越快。
Diabetes Care. 2024 Aug 1;47(8):1386-1394. doi: 10.2337/dc24-0058.
基因组风险评分提供了与缺血性中风临床危险因素相当的预测性能。
Nat Commun. 2019 Dec 20;10(1):5819. doi: 10.1038/s41467-019-13848-1.
4
Artificial intelligence in clinical and genomic diagnostics.人工智能在临床和基因组诊断中的应用。
Genome Med. 2019 Nov 19;11(1):70. doi: 10.1186/s13073-019-0689-8.
5
Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes.估算肾小球滤过率和白蛋白尿变化的联合与主要临床结局风险。
Clin J Am Soc Nephrol. 2019 Jun 7;14(6):862-872. doi: 10.2215/CJN.13391118. Epub 2019 Jun 3.
6
A catalog of genetic loci associated with kidney function from analyses of a million individuals.一项对 100 万人进行的分析显示,与肾功能相关的遗传基因座目录。
Nat Genet. 2019 Jun;51(6):957-972. doi: 10.1038/s41588-019-0407-x. Epub 2019 May 31.
7
On the utilization of polygenic risk scores for therapeutic targeting.关于多基因风险评分在治疗靶点中的应用。
PLoS Genet. 2019 Apr 25;15(4):e1008060. doi: 10.1371/journal.pgen.1008060. eCollection 2019 Apr.
8
Interpreting polygenic scores, polygenic adaptation, and human phenotypic differences.解读多基因评分、多基因适应性和人类表型差异。
Evol Med Public Health. 2018 Dec 27;2019(1):26-34. doi: 10.1093/emph/eoy036. eCollection 2019.
9
Microvascular complications in diabetes: A growing concern for cardiologists.糖尿病的微血管并发症:心脏病学家日益关注的问题。
Int J Cardiol. 2019 Sep 15;291:29-35. doi: 10.1016/j.ijcard.2019.02.030. Epub 2019 Feb 25.
10
Predicting the early risk of chronic kidney disease in patients with diabetes using real-world data.利用真实世界数据预测糖尿病患者的慢性肾脏病早期风险。
Nat Med. 2019 Jan;25(1):57-59. doi: 10.1038/s41591-018-0239-8. Epub 2019 Jan 7.